Literature DB >> 19829144

Severe pulmonary arterial hypertension in a very premature baby with bronchopulmonary dysplasia: normalization with long-term sildenafil.

Salvatore Caputo1, Giuseppe Furcolo, Raffaello Rabuano, Angelo Maria Basilicata, Luigi Maria Pilla, Alfredo De Simone, Brigida Pasquariello, Quirino Ciampi, Gennaro Vetrano, Bruno Villari.   

Abstract

Bronchopulmonary dysplasia is a common adverse outcome of very premature babies treated with long-lasting ventilation and oxygen therapy. Infants with bronchopulmonary dysplasia may develop pulmonary arterial hypertension. We report on severe bronchopulmonary dysplasia in a preterm infant who developed secondary, symptomatic and progressively severe pulmonary arterial hypertension. He was treated with sildenafil for 12 months, with complete resolution of pulmonary arterial hypertension. Eighteen months after therapy discontinuation, the patient was asymptomatic, and his systolic pulmonary artery pressure was normal. Routine use of sildenafil in preterm infants with bronchopulmonary dysplasia and secondary pulmonary arterial hypertension could be the future; large studies should confirm this report.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19829144     DOI: 10.2459/JCM.0b013e328332e745

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  5 in total

Review 1.  Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia.

Authors:  Joseph M Collaco; Lewis H Romer; Bridget D Stuart; John D Coulson; Allen D Everett; Edward E Lawson; Joel I Brenner; Anna T Brown; Melanie K Nies; Priya Sekar; Lawrence M Nogee; Sharon A McGrath-Morrow
Journal:  Pediatr Pulmonol       Date:  2012-07-06

2.  Population pharmacokinetics of sildenafil in extremely premature infants.

Authors:  Daniel Gonzalez; Matthew M Laughon; P Brian Smith; Shufan Ge; Namasivayam Ambalavanan; Andrew Atz; Gregory M Sokol; Chi D Hornik; Dan Stewart; Gratias Mundakel; Brenda B Poindexter; Roger Gaedigk; Mary Mills; Michael Cohen-Wolkowiez; Karen Martz; Christoph P Hornik
Journal:  Br J Clin Pharmacol       Date:  2019-12-15       Impact factor: 3.716

3.  Prophylactic Sildenafil in Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Pilot Randomized, Double-Blinded, Placebo-Controlled Trial.

Authors:  Fouad F Abounahia; Rawia Abu-Jarir; Mohamed F Abounahia; Daoud Al-Badriyeh; Dina Abushanab; Mahmoud Abu-Ghalwa; Ashraf Mansour; Bader Kurdi; Hilal Al-Rifai
Journal:  Clin Drug Investig       Date:  2019-11       Impact factor: 2.859

4.  Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study.

Authors:  Simone Schneider; Mary Bailey; Tracy Spears; Charles R Esther; Matthew M Laughon; Christoph P Hornik; Wesley Jackson
Journal:  BMC Pediatr       Date:  2020-12-14       Impact factor: 2.125

5.  Sildenafil Exposure in the Neonatal Intensive Care Unit.

Authors:  Elizabeth J Thompson; Krystle Perez; Christoph P Hornik; P Brian Smith; Reese H Clark; Matthew Laughon
Journal:  Am J Perinatol       Date:  2018-08-06       Impact factor: 3.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.